LAUSR

Background Knee osteoarthritis is the most common joint disease. Objectives We aimed to compare the efficacy and safety of intra-articular injection of PRP-drived growth factor versus hyaluronic acid (HA) on pain and function of patients with knee osteoarthritis. Methods In this single-blinded randomised clinical trial, patients with symptomatic osteoarthritis of knee were assigned to receive 2 intra-articular injections of PRP-drived growth factor in 3  weeks or 3 weekly injections of HA. Our primary outcome was the mean change from baseline until 2 and 6  months post intervention in scores of visual analogue scale, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Lequesne index. Results A total of 69 patients entered final analysis. The mean age of patients was 58.2 ± 7.41  years and 81.2% were women. Total WOMAC index decreased from 42.9 ± 13.51 to 26.8 ± 13.45 and 24.4 ± 16.54 at 2 and 6  months in the PRGF group (within subjects p = 0.001), and from 38.8 ± 12.62 to 27.8 ± 11.01 and 27.4 ± 11.38 at 2 and 6  months in the HA group (within subjects p = 0.001), respectively (between subjects p = 0.631). There was no significant difference between PRP-drived growth factor and HA groups in patients’ satisfaction and minor complications of injection, whereas patients in HA group reported significantly lower injection-induced pain.Abstract AB0976 – Table 1 WOMAC scores VAS Pain Function Stiffness Total PRGF Baseline 9.2±2.97 30.6±10.09 3.0±2.01 42.9±13.51 7.8±1.78 At 2 month 5.8±2.96 19.5±9.79 1.6±1.66 26.8±13.45 4.9±2.21 At 6 month 5.3±3.60 17.6±11.70 1.5±1.84 24.4±16.54 4.6±2.78 P value within groups 0.0001 0.0001 0.0001 0.0001 0.0001 Hyalgan Baseline 8.7±3.01 27.8±9.62 2.3±1.64 38.8±12.62 7.4±1.48 At 2 month 5.9±2.65 20.6±8.04 1.2±1.39 27.8±11.01 4.8±1.80 At 6 month 5.9±2.79 20.1±7.77 1.3±1.48 27.4±11.38 4.8±2.39 P value within groups 0.0001 0.0001 0.0001 0.0001 0.0001 P value Between Groups 0.847 0.894 0.189 0.985 0.648Abstract AB0976 – Figure 1 Conclusions In 6 months follow up, PRP-drived growth factor and HA, both are effective options to decrease pain and improvement of function in patients with mild to moderate knee osteoarthritis. References [1] Raeissadat, SA, Babaee, M, Rayegani, SM. An overview of platelet products (PRP, PRGF, PRF, etc.) in the Iranian studies [published onlineahead of print July 28, 2017]. Futur Sci OA. doi:10.4155/fsoa-2017-0045. [2] Raeissadat, SA, Rayegani, SM, Babaee, M, Ghorbani, E. The effect of platelet-rich plasma on pain, function, and quality of life of patients with knee osteoarthritis. Pain Res Treat. 2013;2013:165967. Google Scholar [3] Raeissadat, SA, Rayegani, SM, Hassanabadi, H. Knee osteoarthritis injection choices: platelet-rich plasma (PRP) versus hyaluronic acid (a one-year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord. 2015;8:1–8. [4] Raeissadat SA, Rayegani SM, Moridnia M, Dehgolan SR. Intra articular ozone or hyaluronic acid injection: which one is superior in patients with knee osteoarthritis? a 6-month randomized clinical trial.Annals of the Rheumatic Diseases2017;76(Suppl 2):1547–1548. Disclosure of Interest None declared